Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Fiche publication
Date publication
décembre 2014
Journal
Current medical research and opinion
Auteurs
Membres identifiés du Cancéropôle Est :
Dr REILLY Patrick
Tous les auteurs :
Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y
Lien Pubmed
Résumé
To compare the risk of developing uveitis in patients initiating anti-tumor necrosis factor (anti-TNF) agents (adalimumab, etanercept, and infliximab) for ankylosing spondylitis (AS).
Mots clés
Adalimumab, Anti-Inflammatory Agents, therapeutic use, Antibodies, Monoclonal, therapeutic use, Antibodies, Monoclonal, Humanized, therapeutic use, Databases, Factual, Etanercept, Female, Humans, Immunoglobulin G, therapeutic use, Incidence, Infliximab, Male, Middle Aged, Receptors, Tumor Necrosis Factor, therapeutic use, Retrospective Studies, Risk, Spondylitis, Ankylosing, complications, United States, Uveitis, epidemiology, Young Adult
Référence
Curr Med Res Opin. 2014 Dec;30(12):2515-21